Fresenius Kabi Announces FDA Approval Of Adalimumab Biosimilar

Contributor

At Goodwin, we partner with our clients to practice law with integrity, ingenuity, agility, and ambition. Our 1,600 lawyers across the United States, Europe, and Asia excel at complex transactions, high-stakes litigation and world-class advisory services in the technology, life sciences, real estate, private equity, and financial industries. Our unique combination of deep experience serving both the innovators and investors in a rapidly changing, technology-driven economy sets us apart.

Explore Firm Details

Earlier today, Fresenius Kabi announced that the U.S. Food and Drug Administration (FDA) approved IDACIO (adalimumab-aacf), a biosimilar referencing HUMIRA.

United States Food, Drugs, Healthcare, Life Sciences

Authors

Earlier today, Fresenius Kabi announced that the U.S. Food and Drug Administration (FDA) approved IDACIO (adalimumab-aacf), a biosimilar referencing HUMIRA. IDACIO is approved for use in the treatment of chronic autoimmune diseases for all eligible indications of the reference product and, according to Fresenius, is expected to launch in the U.S. from July 2023. As we previously reported, Fresenius announced the launch of IDACIO in Canada in February 2021.

This is the second biosimilar developed by Fresenius to receive FDA approval, following the approval of STIMUFEND in September 2022. IDACIO is the eighth biosimilar referencing HUMIRA to receive FDA approval, following the approval of Coherus' YUSIMRY in December 2021.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Authors